KR20210154214A - 안구 질병의 치료를 위한 화합물 및 방법 - Google Patents
안구 질병의 치료를 위한 화합물 및 방법 Download PDFInfo
- Publication number
- KR20210154214A KR20210154214A KR1020217037540A KR20217037540A KR20210154214A KR 20210154214 A KR20210154214 A KR 20210154214A KR 1020217037540 A KR1020217037540 A KR 1020217037540A KR 20217037540 A KR20217037540 A KR 20217037540A KR 20210154214 A KR20210154214 A KR 20210154214A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- compound
- optionally substituted
- heteroalkyl
- oxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC[C@]([C@](C)([C@@]([C@@](C)N(C)C[C@](C)C[C@](C)([C@@]([C@](C)[C@@]([C@]1C)O[C@@](C[C@@]2(C)OC)O[C@@](C)[C@@]2O)O[C@@]([C@]2OC(C*)O)O[C@](C)C[C@@]2N(C)C)O)O)O)OC1=O Chemical compound CC[C@]([C@](C)([C@@]([C@@](C)N(C)C[C@](C)C[C@](C)([C@@]([C@](C)[C@@]([C@]1C)O[C@@](C[C@@]2(C)OC)O[C@@](C)[C@@]2O)O[C@@]([C@]2OC(C*)O)O[C@](C)C[C@@]2N(C)C)O)O)O)OC1=O 0.000 description 4
- MQTOSJVFKKJCRP-BICOPXKESA-N CC[C@H]([C@](C)([C@@H]([C@@H](C)N(C)C[C@H](C)C[C@](C)([C@@H]([C@@H](C)[C@@H]([C@H]1C)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]([C@@H]2O)O[C@H](C)C[C@@H]2N(C)C)O)O)O)OC1=O Chemical compound CC[C@H]([C@](C)([C@@H]([C@@H](C)N(C)C[C@H](C)C[C@](C)([C@@H]([C@@H](C)[C@@H]([C@H]1C)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]([C@@H]2O)O[C@H](C)C[C@@H]2N(C)C)O)O)O)OC1=O MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- YWMQMASHKIFJEA-OKWAKZRESA-N CC[C@H]([C@@]1(C)OC(N(C)C)O[C@H]1[C@@H](C)N(C)C[C@H](C)C[C@](C)([C@@H]([C@@H](C)[C@@H]([C@H]1C)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]([C@@H]2OC(C)=O)O[C@H](C)C[C@@H]2N(C)C)O)OC1=O Chemical compound CC[C@H]([C@@]1(C)OC(N(C)C)O[C@H]1[C@@H](C)N(C)C[C@H](C)C[C@](C)([C@@H]([C@@H](C)[C@@H]([C@H]1C)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]([C@@H]2OC(C)=O)O[C@H](C)C[C@@H]2N(C)C)O)OC1=O YWMQMASHKIFJEA-OKWAKZRESA-N 0.000 description 1
- RFOZSWUQWYFXAU-NISBFBGCSA-N CC[C@H]([C@](C)([C@@H]([C@@H](C)N(C)C[C@H](C)C[C@](C)([C@@H]([C@@H](C)[C@@H]([C@H]1C)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]([C@@H]2OC(C)=O)O[C@H](C)C[C@@H]2N(C)C)O)O)O)OC1=O Chemical compound CC[C@H]([C@](C)([C@@H]([C@@H](C)N(C)C[C@H](C)C[C@](C)([C@@H]([C@@H](C)[C@@H]([C@H]1C)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]([C@@H]2OC(C)=O)O[C@H](C)C[C@@H]2N(C)C)O)O)O)OC1=O RFOZSWUQWYFXAU-NISBFBGCSA-N 0.000 description 1
- MZSAYVMTHMGLFK-UQDRTEBNSA-N CC[C@H]([C@](C)([C@@H]([C@@H](C)N(C)C[C@H](C)C[C@](C)([C@@H]([C@@H](C)[C@@H]([C@H]1C)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]([C@@H]2OC(C)=O)O[C@H](C)C[C@@H]2N(C)C)O)OC(C)=O)O)OC1=O Chemical compound CC[C@H]([C@](C)([C@@H]([C@@H](C)N(C)C[C@H](C)C[C@](C)([C@@H]([C@@H](C)[C@@H]([C@H]1C)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]([C@@H]2OC(C)=O)O[C@H](C)C[C@@H]2N(C)C)O)OC(C)=O)O)OC1=O MZSAYVMTHMGLFK-UQDRTEBNSA-N 0.000 description 1
- OQXXLYJYRYJJMH-VFTGMAIUSA-N CC[C@H]([C@](C)([C@@H]([C@@H](C)N(C)C[C@H](C)C[C@](C)([C@@H]([C@@H](C)[C@@H]([C@H]1C)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]([C@@H]2OC(CO)=O)O[C@H](C)C[C@@H]2N(C)C)O)O)O)OC1=O Chemical compound CC[C@H]([C@](C)([C@@H]([C@@H](C)N(C)C[C@H](C)C[C@](C)([C@@H]([C@@H](C)[C@@H]([C@H]1C)O[C@@H](C[C@@]2(C)OC)O[C@@H](C)[C@@H]2O)O[C@@H]([C@@H]2OC(CO)=O)O[C@H](C)C[C@@H]2N(C)C)O)O)O)OC1=O OQXXLYJYRYJJMH-VFTGMAIUSA-N 0.000 description 1
- PVXPIJICTUHMAO-UHFFFAOYSA-N COC(CCCCC1SSCC1)=O Chemical compound COC(CCCCC1SSCC1)=O PVXPIJICTUHMAO-UHFFFAOYSA-N 0.000 description 1
- ZQYLDVNTWDEAJI-UHFFFAOYSA-N COC(Cc(cc1)ccc1OC)=O Chemical compound COC(Cc(cc1)ccc1OC)=O ZQYLDVNTWDEAJI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835975P | 2019-04-18 | 2019-04-18 | |
| US62/835,975 | 2019-04-18 | ||
| US202062966482P | 2020-01-27 | 2020-01-27 | |
| US62/966,482 | 2020-01-27 | ||
| PCT/IB2020/000312 WO2020212760A2 (en) | 2019-04-18 | 2020-04-16 | Compounds and methods for the treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210154214A true KR20210154214A (ko) | 2021-12-20 |
Family
ID=72837068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217037540A Ceased KR20210154214A (ko) | 2019-04-18 | 2020-04-16 | 안구 질병의 치료를 위한 화합물 및 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11643429B2 (https=) |
| EP (1) | EP3955937A4 (https=) |
| JP (1) | JP2022529315A (https=) |
| KR (1) | KR20210154214A (https=) |
| CN (1) | CN114007625A (https=) |
| AU (1) | AU2020259997B2 (https=) |
| CA (1) | CA3136369A1 (https=) |
| IL (1) | IL287280A (https=) |
| WO (1) | WO2020212760A2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240016209A (ko) | 2022-07-28 | 2024-02-06 | 스미또모 가가꾸 가부시키가이샤 | 편광 필름의 제조 방법 및 제조 장치 |
| WO2024101918A1 (ko) * | 2022-11-11 | 2024-05-16 | 주식회사 메디치바이오 | 리포-하이드록삼산 유도체 및 이의 약학적 용도 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3955937A4 (en) | 2019-04-18 | 2023-01-18 | Azura Ophthalmics Ltd. | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES |
| JP7700045B2 (ja) | 2019-04-18 | 2025-06-30 | アズーラ オフサルミックス エルティーディー． | 眼障害を処置するための化合物および方法 |
| IL302173A (en) * | 2020-10-21 | 2023-06-01 | Azura Ophthalmics Ltd | Compounds and methods for the treatment of ocular disorders |
| CN116940570A (zh) * | 2020-10-21 | 2023-10-24 | 阿祖拉眼科有限公司 | 用于治疗眼部病症的化合物和方法 |
| EP4419502A4 (en) * | 2021-10-20 | 2025-10-29 | Azura Ophthalmics Ltd | COMPOUNDS AND METHODS FOR THE TREATMENT OF SKIN AND OCULAR DISORDERS |
| WO2024134266A1 (en) * | 2022-12-20 | 2024-06-27 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of dermal and ocular disorders |
| WO2025012700A2 (en) * | 2023-07-07 | 2025-01-16 | Azura Ophthalmics Ltd. | Compositions and methods for the treatment of autoimmune disorders |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| US5350839A (en) * | 1990-10-15 | 1994-09-27 | Taisho Pharmaceutical Co., Ltd. | 2'-position modified compound of erythromycin or its derivative |
| WO1995018604A1 (en) * | 1994-01-11 | 1995-07-13 | Ciba-Geigy Ag | Topical treatment of ocular photophobia |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| US7056893B2 (en) | 1999-03-31 | 2006-06-06 | Insite Vision, Inc. | Topical treatment for prevention of ocular infections |
| EP1101769A3 (en) * | 1999-11-18 | 2001-10-24 | Pfizer Products Inc. | Nitrogen containing erythromycin derivatives |
| RU2263117C2 (ru) * | 2001-04-27 | 2005-10-27 | Пфайзер Продактс Инк. | Способ получения 4"-замещенных производных 9-деоксо-9а-аза-9а-гомоэритромицина а |
| FR2832637B1 (fr) * | 2001-06-07 | 2004-07-30 | Lefaix Marie Therese Droy | Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface |
| AU2003219770B2 (en) * | 2002-02-15 | 2008-10-09 | Merckle Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| GB0310984D0 (en) * | 2003-05-13 | 2003-06-18 | Glaxo Group Ltd | Novel compounds |
| GB0310962D0 (en) * | 2003-05-13 | 2003-06-18 | Glaxo Group Ltd | Novel compounds |
| GB0310980D0 (en) * | 2003-05-13 | 2003-06-18 | Glaxo Group Ltd | Novel compounds |
| CN1837225A (zh) * | 2005-08-23 | 2006-09-27 | 济南思创生物技术有限公司 | 阿奇霉素衍生物及其制法和药物应用 |
| GB0609373D0 (en) * | 2006-05-11 | 2006-06-21 | Glaxo Group Ltd | Macrolones |
| PE20090879A1 (es) * | 2007-07-30 | 2009-07-25 | Glaxosmithkline Zagreb | DERIVADOS 9-DESOXO-9a-METIL-9a-AZA-9a-HOMOERITROMICINA A COMO AGENTES ANTIMALARICOS |
| WO2010086350A1 (en) * | 2009-01-30 | 2010-08-05 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | 9-deoxo- 9a-methyl- 9a- aza- 9a-h0m0erythr0mycin a derivatives for the treatment of neutrophil dominated inflammatory diseases |
| WO2011100769A2 (en) * | 2010-02-15 | 2011-08-18 | Synovo Gmbh | Kinase modulators for the treatment of cancer |
| CA2840626A1 (en) * | 2011-06-29 | 2013-01-03 | Insite Vision Incorporated | Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence |
| AU2013239679A1 (en) * | 2012-03-27 | 2014-10-30 | Michael W. BURNET | Anti-inflammatory macrolides |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| JP2019513775A (ja) | 2016-04-19 | 2019-05-30 | アズーラ オフサルミックス エルティーディー． | 角化症の処置のための組成物 |
| WO2018161039A1 (en) * | 2017-03-03 | 2018-09-07 | Synovo Gmbh | Novel anti-infective and anti-inflammatory compounds |
| EP3600272A4 (en) | 2017-03-29 | 2021-01-13 | Azura Ophthalmics Ltd. | MEANS OF INCREASING LIPID SECRETION OF THE MEIBOMAN GLAND |
| WO2018215638A1 (en) * | 2017-05-26 | 2018-11-29 | Novaliq Gmbh | Pharmaceutical compositions comprising azithromycin |
| EP3955937A4 (en) | 2019-04-18 | 2023-01-18 | Azura Ophthalmics Ltd. | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES |
-
2020
- 2020-04-16 EP EP20790702.3A patent/EP3955937A4/en active Pending
- 2020-04-16 CA CA3136369A patent/CA3136369A1/en active Pending
- 2020-04-16 CN CN202080044806.4A patent/CN114007625A/zh active Pending
- 2020-04-16 KR KR1020217037540A patent/KR20210154214A/ko not_active Ceased
- 2020-04-16 AU AU2020259997A patent/AU2020259997B2/en active Active
- 2020-04-16 WO PCT/IB2020/000312 patent/WO2020212760A2/en not_active Ceased
- 2020-04-16 JP JP2021559179A patent/JP2022529315A/ja active Pending
-
2021
- 2021-04-05 US US17/222,821 patent/US11643429B2/en active Active
- 2021-10-14 IL IL287280A patent/IL287280A/en unknown
-
2023
- 2023-03-06 US US18/117,759 patent/US20230348517A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240016209A (ko) | 2022-07-28 | 2024-02-06 | 스미또모 가가꾸 가부시키가이샤 | 편광 필름의 제조 방법 및 제조 장치 |
| WO2024101918A1 (ko) * | 2022-11-11 | 2024-05-16 | 주식회사 메디치바이오 | 리포-하이드록삼산 유도체 및 이의 약학적 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL287280A (en) | 2021-12-01 |
| EP3955937A4 (en) | 2023-01-18 |
| JP2022529315A (ja) | 2022-06-21 |
| WO2020212760A2 (en) | 2020-10-22 |
| AU2020259997B2 (en) | 2025-08-07 |
| AU2020259997A1 (en) | 2021-11-25 |
| CA3136369A1 (en) | 2020-10-22 |
| US20230348517A1 (en) | 2023-11-02 |
| US11643429B2 (en) | 2023-05-09 |
| US20210230205A1 (en) | 2021-07-29 |
| WO2020212760A3 (en) | 2021-02-25 |
| CN114007625A (zh) | 2022-02-01 |
| EP3955937A2 (en) | 2022-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20210154214A (ko) | 안구 질병의 치료를 위한 화합물 및 방법 | |
| JP7700045B2 (ja) | 眼障害を処置するための化合物および方法 | |
| KR20230110515A (ko) | 눈 장애의 치료를 위한 화합물 및 방법 | |
| AU2020259996A1 (en) | Compounds and methods for the treatment of ocular disorders | |
| KR20230110514A (ko) | 안구 장애의 치료를 위한 화합물 및 방법 | |
| US20250042931A1 (en) | Compounds and methods for the treatment of ocular disorders | |
| KR20230110516A (ko) | 눈 장애의 치료를 위한 화합물 및 방법 | |
| CN116940570A (zh) | 用于治疗眼部病症的化合物和方法 | |
| HK40068817A (en) | Compounds and methods for the treatment of ocular disorders | |
| HK40068671A (en) | Compounds and methods for the treatment of ocular disorders | |
| HK40100091A (zh) | 用於治疗眼部病症的化合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D13-X000 | Search requested |
St.27 status event code: A-1-2-D10-D13-srh-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |